# A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

> **NCT01983501** · PHASE1 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 57 (actual)

## Conditions studied

- HER2 Positive Breast Cancers

## Interventions

- **DRUG:** Tucatinib (ONT-380)
- **DRUG:** T-DM1

## Key facts

- **NCT ID:** NCT01983501
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-28
- **Primary completion:** 2017-10-10
- **Final completion:** 2020-09-03
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2020-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01983501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01983501, "A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01983501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*